Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers.

Kai Lu,Hsin-Chiao Wang,Yi-Chen Tu,Cheng-Chung Chang,Pei-Jen Lou,Ta-Chau Chang,Jing-Jer Lin

Journal of the National Cancer Institute（2023）

引用 1|浏览1

暂无评分

摘要

These findings unveil a synthetic lethal strategy to prevent and to inhibit EGFR-mutated lung cancers with acquired osimertinib-resistance. G4 ligands have the potential to be integrated into current osimertinib-based treatment regimens.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要